Drug Profile
Research programme: drug discovery - Genfit/Sanofi
Alternative Names: SAN/GFT 2; SAVX1 programmeLatest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Genfit; sanofi-aventis
- Developer Genfit; Sanofi
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis; Inflammation; Kidney disorders; Type 2 diabetes mellitus
- Discontinued Neurodegenerative disorders
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Kidney-disorders in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in France